A Study of linifanib (ABT-869) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-jRCT2080221285
- Lead Sponsor
- Abbott Japan Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 12
2. The subject must have cytologically or histologically confirmed non-squamous NSCLC
3. The subject must have advanced or metastatic (Stage IV [According to AJCC staging manual, 7th edition]) disease that is not amenable to surgical resection or radiation with curative intent.
4. The subject must have not received prior chemotherapy for NSCLC.
18. The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.
1. The subject has hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
2. The subject has received any anti-cancer therapy for treatment of NSCLC including investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies, hormonal, targeted agents, biologic therapy or cytotoxic chemotherapy which includes neo-adjuvant or adjuvant chemotherapy for NSCLC.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method